Product Name: Cefmenoxime

Synonyms: CEFMENOXIME;(6r-(6alpha,7beta(z)))-7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6α,7β(Z)]]-;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R,7R)-;AB 50912;SCE 1365;Cefotaxime Isomer;[6R-[6α，7β(Z)]]-7-[[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-y1)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oet-2-ene-2-carboxylic acid

CAS: 65085-01-0

MF: C16H17N9O5S3

MW: 511.56

EINECS: 278-299-4

Product Categories: Pharmaceutical intermediate

Mol File: 65085-01-0.mol

Cefmenoxime Structure

Cefmenoxime Chemical Properties

density 1.96±0.1 g/cm3(Predicted)

pka 2.61±0.50(Predicted)

CAS DataBase Reference 65085-01-0(CAS DataBase Reference)

Safety Information

MSDS Information

Cefmenoxime Usage And Synthesis

Uses Antibacterial.

Definition ChEBI: A third-generation cephalosporin antibiotic, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position and a [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl group at the 3-position.

Brand name Cefmax (TAP).

Antimicrobial activity A semisynthetic cephalosporin supplied as the hydrochloride. Its activity is very similar to that of cefotaxime. A 500 mg intramuscular injection achieves a plasma concentration of 15 mg/L after 40 min. A concentration of 200 mg/L is attained after intravenous administration of 1 g. The plasma half-life is c. 1 h. Around 77% is protein bound. Probenecid increases peak plasma levels and extends the plasma half-life to 1.8 h. Therapeutic concentrations are achieved in CSF. There is a degradation product with a long half-life (around 40 h), but 80–92% of the drug is recovered unchanged from the urine. In patients with renal insufficiency, no significant relation was found between creatinine clearance and peak serum concentrations but there was a linear relationship with plasma half-life and total body clearance. About 10% of the dose appears in the feces, mostly extensively degraded, possibly by the fecal flora.

Toxicity, side effects and clinical use are those common to group 4 cephalosporins.